Searched for
DANISH DRUGMAKER
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- Novo Nordisk hit by cyber incident, probes data breachDanish drugmaker Novo Nordisk has confirmed a security incident. Unauthorised access to internal IT systems occurred. Certain non-public da...
- India's GCC model shifts from cost to capability as AI, talent strains biteIndia's dominance in global capability centres is evolving. These hubs are now integrated, managing complex functions beyond support. Risin...
- Global firms bring more work in-house at India hubs on AI boostThe shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...
- Global firms bring more work in-house at India hubs on AI boostGlobal firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...
- Novo Nordisk uses AI to fast-track drug launches, expand India roleNovo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarityEli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...
- Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapyLast October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of the therap...
- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Eli Lilly Foundayo weight-loss pill vs Novo Nordisk Wegovy oral obesity treatment tablets: Which medicine is the most prescribed across U.S.?Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- HC seeks Novo Nordisk's reply on Natco plea to revoke patentThe Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cance...
- Novo Nordisk shares jump 10% after US approves Wegovy pillNovo Nordisk shares jumped 10% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, giving the Danish dru...
- US FDA issues 'Official Action Indicated' status to Sun Pharma’s Baska facility after inspectionSun Pharmaceutical Industries Ltd announced that its Baska manufacturing facility has been classified as Official Action Indicated (OAI) by...
- Tech stocks pull European shares lower; earnings in focusEuropean shares dipped to a two-week low on Wednesday, mirroring global investor nervousness over elevated equity valuations. Technology st...
- AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolioAstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...
Load More
